Genta has built a broad portfolio of proprietary products in various stages of clinical development. The Company’s lead compound, Genasense (oblimersen sodium) Injection, has been studied in over 2,500 patients with a wide variety of tumor types. At Genta, we are aggressively leveraging our expertise in clinical oncology research by expanding and diversifying our R&D pipeline.
Patient Information about malignant melanoma, including links to melanoma patient advocacy groups.
Genta is building a portfolio of products targeted against some of the most deadly cancers and related conditions facing patients today. With three products in the pipeline and ongoing trials in all phases of development (Preclinical to Phase 3), Genta is committed to developing innovative products to better the lives of people with cancer.
Latest Genta Announcements
Genasense® Mechanism of Action Video
Tesetaxel Clinical Status
How Oral Gallium Works
